NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Diagnostics & Research · USD

Labcorp Holdings Inc. (LH) Stock Analysis

Labcorp Holdings Inc. (LH) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.

LH

$326.89

−$4.61 (−1.39%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LH with… →

LH Key Statistics

As of Sep 4, 2026
Trading
Open
$328.00
Previous Close
$331.50
Day's Range
326.16–330.56
52-Week Range
244.52–341.80
Volume
438.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.85
Valuation
Market Cap
$26.51B
P/E Ratio
27.40
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
16.49
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.30
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.85
EPS (ttm)Profit attributable to each share over the last twelve months.
11.93
Financials (FY)
Revenue (FY)
$13.95B+7.25%
Net Income (FY)
$876.50M+17.49%
Profit marginThe share of revenue left as profit after all costs and taxes.
6.99%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
81.10M
1-Year Return
+19.97%
Dividend and dates
Dividend
$2.88+0.87%
Ex-Dividend Date
August 28, 2026
Earnings Date
November 3, 2026estimated
Avg Volume
678.66K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+31.26%
2025+10.62%
2024+2.22%
2023+13.82%
2022−24.41%
2021+54.36%
2020+20.32%
2019+33.88%
2018−20.78%
2017+24.25%
2016 (partial year)−8.07%

As of September 4, 2026.

LH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$13.95B$876.50M6.3%
2024$13.01B$746.00M5.7%
2023$12.16B$418.00M3.4%
2022$11.86B$1.28B10.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$13.95B$4.01B$1.52B$876.50M6.3%
2024$13.01B$3.62B$1.14B$746.00M5.7%
2023$12.16B$3.36B$1.12B$418.00M3.4%
2022$11.86B$3.71B$1.75B$1.28B10.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LH Dividend History

$2.88+0.0% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$2.163—
2025$2.884+0.0%
2024$2.884+7.6%
2023$2.684+44.3%
YearDividends per sharePaymentsChange
2026 (partial year)$2.163—
2025$2.884+0.0%
2024$2.884+7.6%
2023$2.684+44.3%
2022$1.863—

Most recent payment: $0.72 per share, ex-dividend August 28, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

LH Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricLHDiagnostics & Research medianvs median
P/E27.4033.0817% below
P/S ratio1.854.9963% below
Profit margin6.99%0.00%7.0 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Labcorp Holdings Inc. (LH) at $26.51B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 71,000 employees.

Over the past 52 weeks the price has ranged from $244.52 to $341.80. LH last closed at $326.89 on September 4, 2026. That is −$4.61 (−1.39%) against the previous close. The latest close sits 33.69% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $13.95B. Against the prior fiscal year total of $13.01B, that is a change of +7.25%. The same year closed with net income of $876.50M. That is +17.49% against the prior fiscal year. Profit margin runs at 6.99%. That is 7 percentage points above the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to 11.93.

Across the 4 fiscal years on file, revenue moves from $11.86B in 2022 to $13.95B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

LH trades at a trailing price-to-earnings ratio of 27.4. That is 17.17% below the Diagnostics & Research median of 33.08. The forward P/E on file is 16.49. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.3. Measured against sales, the shares trade at 1.85 times revenue. On price-to-sales that is 62.97% below the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

Beta against the wider market is reported at 0.85. Daily returns over the trailing 10 years annualize to a volatility of 26.81%. Over the trailing twelve months the price has returned +19.97%. Across 10 years the annualized return works out at +11.29%.

Growth & Income

The trailing dividend yield is 0.87%. That is 0.1 percentage points above the Diagnostics & Research median yield of 0.76%. The indicated annual rate is $2.88 a share. The ex-dividend date on file is August 28, 2026. Dividends are recorded for 5 calendar years; 2026 shows 3 payments totalling $2.16 a share. The year before, 2025, totalled $2.88 a share.

The strongest complete calendar year on file is 2021 at +54.36%; the weakest is 2022 at −24.41%. Of the 9 complete calendar years on file, 7 finished higher. 2026 is still running; the price is +31.26% year to date.

Peer Comparison

Labcorp Holdings Inc. (LH) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Labcorp Holdings Inc. LH $26.51B 27.4
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Labcorp Holdings Inc. trades at a P/E of 27.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Labcorp Holdings Inc.

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Visit website →